This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pharma And Payers - Building Better Relationships

NEW YORK, Oct. 30, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Pharma and Payers – Building Better Relationships–-Building-Better-Relationships.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Changes in the healthcare landscape have put payers (public and private) under mounting pressure to reduce the cost of care, and given them much greater influence over market access to new medicines.

In this new environment, regulatory approval of new drugs no longer guarantees favourable pricing and formulary placement. Instead, payers focus increasingly on value to determine pricing and access.

Drug developers need to understand the value review process, and adapt their organisation to engaging payers early in the journey. More profoundly, pharma companies must find ways to evolve their current transactional, and even adversarial, relationships with payers to more collaborative ones. After all, Pharma and payers share the same ultimate goals – to lower costs and improve care.

This new report helps Pharma and payers build a "win-win" relationship; by understanding each other's needs, and by exploring new opportunities for collaboration.

Report Overview This extensive report includes a wealth of information and tools that empower Pharma and payers to work together more effectively, with the ultimate goal of offering patients access to life-saving drugs, biologics, and vaccines.

After painting a detailed picture of the current environment (including explaining regional payer systems, and key factors driving change), the report offers a fascinating exploration of "what payers want". You'll learn about the primary ways in which payers are measuring outcomes (e.g., QALY, CER, pragmatic clinical trials), and discover best practices in resource allocation, organisation, communication, and accountability.

The report includes real case studies of successful pharma-payer partnerships (such as risk-sharing agreements, clinical outcomes studies), and draws on expert opinions and advice from more than a dozen of the world's foremost thought leaders and executives in this space.

Key Report Features Detailed insights into what payers want from Pharma (and vice versa) Recent case studies of collaborations between major pharma companies and payers Practical advice on meeting payers' needs and tackling potential problems Review of the growing influence of patients/consumers Description of different types of payers Guide to the payer frameworks in key markets (US, UK, and the leading European pharma markets: Germany, France)

Key Benefits

Learn from successful collaborations between payers and Pharma Understand what payers expect and want from Pharma Improve Pharma-payer communications Optimise your organisational structure to meet payer needs Be aware of potential pitfalls Generate successful drug pricing and formulary placement discussions Be ready for future developments

Who Should Read This Report?

Pharma executives in Market Access, Pricing, Reimbursement, Strategic Planning, and Marketing Payer executives and representatives, including health insurance providers, government payers, pharmacists, social security, and local health authorities Executives in Clinical Development Health Economics and Outcomes Research leaders

Key Questions Answered

What kinds of data (e.g., around safety and efficacy) are most useful for improving market access? What are the key differences and common denominators between the payers in the US and key European markets? Who are the best people to represent Pharma in payer negotiations? At what stage of drug development should the payers, or pricing and reimbursement consultants, become involved? What kind of risk-sharing arrangements can be made between pharma and payers? What opportunities are there for win-win collaborations?

Expert Views Include:

Steve Phillips, director, Health Policy and Reimbursement, Johnson and Johnson — government health policy leader and advisor to all J&J operating companies Tehseen Salimi, vice president, Customer Medical Synergies, Sanofi-Aventis — payer interaction leader, scheduled to speak at Evidence Based Reimbursement Summit 2012 Dr. Marcus Wilson, vice president, WellPoint, HealthCore Inc — pioneer in real-world outcomes research Terri Bernacchi, managed care pharmacist/consultant, engaged with several US health plans and IMS Health Managed Market Services — expert and author on payer engagement Michael Hurwich, president, Strategic Pricing Management Group — one of the world's foremost pricing, revenue & strategy management consultants Cyndy Nayer, president and founder, Center of Health Value Innovation (CHVI) — thought leader on value-based benefit design And many more renowned thought leaders and senior industry executives.

Key Quotes

"It is no longer simply about drug cost but total cost of care to demonstrate a product's value. Pharma is beginning to understand that." Dr. Marcus Wilson, vice president, WellPoint, HealthCore Inc

"If drugmakers haven't got the relevant health economic data together to support the price of a new drug then it's never going to float." Michael Morgan-Curran, director, mHealth Diabetes, GSMA; director/owner, MM-C Innovative Solutions

"Each payer is different and to create and maintain long term mutually beneficial relationships, pharmaceutical companies must understand a payer's environment, the way they work, their needs and drivers." Elliot Rosen, managing director, Accession Healthcare Consultancy

Executive Summary Introduction > Payers: who's who> US payers> European payers> Payer organisations in the UK ( England and Wales)> Scotland> France> GermanyChanging landscape > Rapid growth of high-priced biologics and specialty drugs> A shift from volume-driven contracts to value-based pricing> Patient non-adherence: a costly problem> Payers demand real-world data> Health economic data: is it good enough for payers?> Patient powerThe drug manufacturer conundrum The changing drug manufacturer-payer relationship What payers want > Measuring health outcomes> QALY and ICER> Comparative effectiveness research, pragmatic clinical trials and adoptive licensing agreements> Improving market access via adaptive licensing> Market access agreements: health outcomes and risk-sharing schemes> Innovative US drug manufacturer-payer alliances and partnerships> Building better relationshipsThe new drugmaker-payer relationship > HTA and value-based pricing are here to stay> CER is becoming the new normal> Quality of economic modelling and health outcomes data is vital> Cost of a drug vs cost of care> Best-price frameworks> When to approach payers> Moving From transaction to collaboration builds trust> Sharing and exchanging patient dataOpening new communication channels is essential > Create an environment of accountabilityMoving forward together Conclusions

To order this report: Drug_and_Medication Industry: Pharma and Payers – Building Better Relationships

__________________________Contact Nicolas: nicolasbombourg@reportlinker.comUS: (805)-652-2626Intl: +1 805-652-2626

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 -0.60%
FB $101.91 0.90%
GOOG $683.11 -0.15%
TSLA $150.47 4.73%
YHOO $26.76 -1.25%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs